Synthesis and characterization of TiO2 nanotubes as anodic material in lithium-ion batteries

The aim of this work is to analyze the efficiency of titania nanotubes acting as anode for lithium-ion batteries. The titania nanotubes has been obtained using an anodization process in a ethylene glycol solution, containing ammonium fluoride and a small quantity of water. After a heat treatment, needed to crystallize the material in the anatase form, the nanotubes has been analyzed in their performance as anode in a Li-ion battery. Structural and morphologic characterization of the titania nanotubes have been studied using XRD and SEM analysis, while the galvanostatic cycles has been collected in order to examine the electrochemical performance as electrodic material. Finally, a comparison of the electrochemical performance between our samples and commercial nanostructured titanium oxide, has been made, obtaining that the TiO2 nanotube electrodes treatmen reduces the overall cell voltage and provides good retention capacity on cycling and higher capacity at all used C-rate

Innovative nanomaterials for fuel cells fed with biogas

Challenges on sustainability promote research policy focused on renewable-energy technology development in order to enhance global energy security, local energy independence, environmental protection and economic growth. Biomass resources offer renewable energies that can play a key role in the current global strategies for reducing greenhouse gas emissions by partially replacing fossil fuels. The conversion of biomass chemical energy into electrical energy and cogenerated heat can be obtained by fuel cells. In particular, molten carbonate fuel cell (MCFC) is the most suitable device for bioenergy production because it can be fed directly with biogas, whose primary constituents all improve the performance of the cell. However hydrogen sulfide, which is the main biogas impurity, poisons the traditional nickel based anode, affecting the power and the endurance of the cell. In order to overcome this problem, an innovative anode material that resists against the sulfide corrosions has been developed. This material, made of a nanostructured and porous nickel support covered with a thin layer of ceria, exhibits high sulfur tolerance and recovering capability

Innovative nanomaterials for fuel cells fed with biogas

Challenges on sustainability promote research policy focused on renewable-energy technology development in order to enhance global energy security, local energy independence, environmental protection and economic growth. Biomass resources offer renewable energies that can play a key role in the current global strategies for reducing greenhouse gas emissions by partially replacing fossil fuels. The conversion of biomass chemical energy into electrical energy and cogenerated heat can be obtained by fuel cells. In particular, molten carbonate fuel cell (MCFC) is the most suitable device for bioenergy production because it can be fed directly with biogas, whose primary constituents all improve the performance of the cell. However hydrogen sulfide, which is the main biogas impurity, poisons the traditional nickel based anode, affecting the power and the endurance of the cell. In order to overcome this problem, an innovative anode material that resists against the sulfide corrosions has been developed. This material, made of a nanostructured and porous nickel support covered with a thin layer of ceria, exhibits high sulfur tolerance and recovering capability

MicroRNA133 and microRNA499 exert synergistic effect on cardiac differentiation

n/

Hairy cell leukemia in kidney transplantation: lesson from a rare disorder.

We report here on the diagnosis and successful treatment of a case of hairy cell leukemia (HCL) that arose 15 years after kidney transplantation in a 51-year-old patient. As soon as the diagnosis was made, HCL was treated with 2-CDA, obtaining complete hematological remission. Immunosuppression with the calcineurin inhibitor cyclosporin was maintained, and the graft was preserved. In kidney transplant recipients supported with immunosuppressive drugs, post-transplant lymphoproliferative diseases (PTLDs) are frequent and typically related to immunosuppression via a loss of control of infectious/EBV-related proliferative stimuli. To date, HCL has not been considered among PTLDs. Recently, however, the oncogenic mutation V600E of the BRAF protein kinase has been found to be a hallmark of HCL, and calcineurin inhibitors have been shown to interfere with signaling downstream of V600E BRAF early on by counteracting senescence-associated mechanisms that protect against the oncogenic potential of the mutated kinase. Such a biochemical link between the oncogene-dependent signaling and calcineurin inhibitor activities suggests that HCL in transplanted patients might be a peculiar type of PTLD based on the presence of a specific mutation. This mechanism might also be involved in other neoplasias bearing the same or similar mutations, such as melanoma and non-melanoma skin cancer

Law as a Tool for Preventing Chronic Diseases: Expanding the Spectrum of Effective Public Health Strategies

Law, which is a fundamental element of effective public health policy and practice, played a crucial role in many of public health's greatest achievements of the 20th century. Still, conceptual legal frameworks for the systematic application of law to chronic disease prevention and control have not been fully recognized and used to address public health needs. Development and implementation of legal frameworks could broaden the range of effective public health strategies and provide valuable tools for the public health workforce, especially for state and local health department program managers and state and national policy makers. In an effort to expand the range of effective public health interventions, the Centers for Disease Control and Prevention will work with its partners to explore the development of systematic legal frameworks as a tool for preventing chronic diseases and addressing the growing epidemic of obesity, heart disease, stroke, and other chronic diseases and their risk factors

COVID-19 and kidney transplantation: an Italian Survey and Consensus

Italy was the first Western country to face the COVID-19 pandemic. Here we report the results of a national survey on kidney transplantation activity in February and March 2020, and the results of a three-round Delphi consensus promoted by four scientific societies: the Italian Society of Organ Transplantation, the Italian Society of Nephrology, the Italian Society of Anesthesia and Intensive Care, and the Italian Group on Antimicrobial Stewardship. All 41 Italian transplant centers were invited to express their opinion in the Delphi rounds along with a group of seven experts. The survey revealed that, starting from March 2020, there was a decline in kidney transplantation activity in Italy, especially for living-related transplants. Overall, 60 recipients tested positive for SARS-CoV2 infection, 57 required hospitalization, 17 were admitted to the ICU, and 11 died. The online consensus had high response rates at each round (95.8%, 95.8%, and 89.5%, respectively). Eventually, 27 of 31 proposed statements were approved (87.1%), 12 at the first or second round (38.7%), and 3 at the third (9.7%). Based on the Italian experience, we discuss the reasons for the changes in kidney transplantation activity during the COVID-19 pandemic in Western countries. We also provide working recommendations for the organization and management of kidney transplantation under these conditions

mTOR inhibitors effects on regulatory T cells and on dendritic cells.

The mammalian target of rapamycin (mTOR), a cytoplasmic serine/threonine kinase, represents a key biologic "switch" modulating cell metabolisms in response to environmental signals and is now recognized as a central regulator of the immune system. There is an increasing body of evidence supporting the hypothesis that mTOR inhibitors exhibit several biological properties in addition to immunosuppression, including anti-neoplastic effects, cardio-protective activities, and an array of immunomodulatory actions facilitating the development of an operational graft tolerance. The biological mechanisms explaining how mTOR inhibition can enable a tolerogenic state are still largely unclear. The induction of transplant tolerance might at the same time decrease rejection rate and minimize immunosuppression-related side effects, leading to an improvement in long-term graft outcome. In this scenario, T cell immunoregulation has been defined as the hallmark of peripheral tolerance. Two main immunologic cell populations have been reported to play a central role in this setting: regulatory T cells (Tregs) and dendritic cells (DCs). In this review we focus on mTOR inhibitors effects on Treg and DCs differentiation, activation, and function in the transplantation setting

Care of patients with ST-elevation myocardial infarction: an international analysis of quality indicators in the acute coronary syndrome STEMI Registry of the EURObservational Research Programme and ACVC and EAPCI Associations of the European Society of Cardiology in 11 462 patients

Aims To use quality indicators to study the management of ST-segment elevation myocardial infarction (STEMI) in different regions. Methods and results Prospective cohort study of STEM I within 24 h of symptom onset (11 462 patients, 196 centres, 26 European Society of Cardiology members, and 3 affiliated countries). The median delay between arrival at a percutaneous cardiovascular intervention (PCI) centre and primary PCI was 40 min (interquartile range 20-74) with 65.8% receiving PCI within guideline recommendation of 60 min. A third of patients (33.2%) required transfer from their initial hospital to one that could perform emergency PCI for whom only 27.2% were treated within the quality indicator recommendation of 120 min. Radial access was used in 56.6% of all primary PCI, but with large geographic variation, from 76.4 to 9.1%. Statins were prescribed at discharge to 98.7% of patients, with little geographic variation. Of patients with a history of heart failure or a documented left ventricular ejection fraction <= 40%, 84.0% were discharged on an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker and 88.7% were discharged on beta-blockers. Conclusion Care for STEMI shows wide geographic variation in the receipt of timely primary PCI, and is in contrast with the more uniform delivery of guideline-recommended pharmacotherapies at time of hospital discharge. [GRAPHICS]